Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE
    Publication number: 20170239265
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: May 5, 2017
    Publication date: August 24, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders
    Publication number: 20170231983
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Application
    Filed: May 2, 2017
    Publication date: August 17, 2017
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Hiroshi YAMASHITA, Nobuaki ITO, Shin MIYAMURA, Kunio OSHIMA, Jun MATSUBARA, Hideaki KURODA, Haruka TAKAHASHI, Satoshi SHIMIZU, Tatsuyoshi TANAKA
  • HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE
    Publication number: 20170224713
    Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents —O— or —CH2—; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
    Type: Application
    Filed: April 24, 2017
    Publication date: August 10, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Nobuaki ITO, Hirofumi SASAKI, Kuninori TAI, Tomoichi SHINOHARA
  • AGENT FOR IMPROVING OR MAINTAINING QOL
    Publication number: 20170216379
    Abstract: [Object] An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. [Method for Achieving the Object] A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mina TSUBOUCHI, Takao SAITO, Masamichi TOBA, Noriyuki KOUDA, Shoji SHINKAI
  • OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION
    Publication number: 20170216260
    Abstract: The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Minoru OKADA, Masaya KATO, Norifumi SATO, Tetsuyuki UNO, Hideki KITAGAKI, Junpei HARUTA, Hidetaka HIYAMA, Tomonori SHIBATA
  • ORAL FORMULATION
    Publication number: 20170202833
    Abstract: Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and water, and a substrate for oral formulation, which contains sugar alcohol; the above-mentioned hydrophilic polysaccharides; a gelling agent; and water.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Taro IWAMOTO, Nobuyuki KURAHASHI, Yoshikazu OKA, Chikako TAKEDA
  • Method and apparatus for manufacturing nucleated tablets
    Patent number: 9707729
    Abstract: Provided is a method and apparatus for manufacturing nucleated tablets in each of which a nucleus is positioned in a precise manner. In the tablet manufacturing machine (1), granules are charged in a mortar and then compressed by pestles while the mortar and the pestles travel along a cyclic path extending from a point and then back to the point. The path has a substantially straight path portion where the mortar and the pestles travel substantially straightly.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: July 18, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Hiroshi Inaka
  • Cyanopyrimidine derivative
    Patent number: 9708292
    Abstract: The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: July 18, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Norifumi Sato, Yohei Yuki, Hisashi Shinohara, Yasuhiro Takeji, Kuni Ito, Daisaku Michikami, Keisuke Hino, Hiroyuki Yamazaki
  • ENERGY MALNUTRITION EVALUATION FOR LIVER DISEASE TEST SUBJECT
    Publication number: 20170199172
    Abstract: A method for measuring energy malnutrition in a liver disease test subject, a method for determining whether a liver disease test subject is in an energy malnutrition state, a method for determining the necessity of nutrition therapy for a liver disease test subject having energy malnutrition, a composition usable in these methods, and the like are provided. The method for measuring energy malnutrition in a liver disease test subject includes the steps of collecting expired air containing labeled carbon dioxide that is generated in the body of a liver disease test subject by being converted from a composition containing, as an active ingredient, glucose labeled with at least one isotope C; and determining the ratio of labeled CO2 amount to unlabeled CO2 amount, or the ratio of labeled CO2 amount to total CO2 amount in expired air.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto INADA, Jun-ichi KUNIZAKI, Kazuki TOBITA
  • PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS
    Publication number: 20170198293
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 13, 2017
    Applicants: Mie University, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Esteban C. GABAZZA, Tetsu KOBAYASHI, Hidekazu TOYOBUKU, Ayako FUKUDA, Tetsuya HASEGAWA
  • DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE
    Publication number: 20170196877
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
    Patent number: 9694009
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: July 4, 2017
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • MEDICAL TABLET, AND MANUFACTURING METHOD AND MANUFACTURING APPARATUS FOR MEDICAL TABLET
    Publication number: 20170181969
    Abstract: An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of being positioned above pharmaceutical powder filled in a die hole before compression. The IC chip is supplied by a pusher.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 29, 2017
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., OMORI MACHINERY CO., LTD.
    Inventors: Etsuhiro MAEDA, Yasutoshi KOHATA
  • TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
    Publication number: 20170165258
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS
    Publication number: 20170166524
    Abstract: The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 15, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Muneaki KURIMURA, Shinichi TAIRA, Takahiro TOMOYASU, Nobuaki ITO, Kuninori TAI, Noriaki TAKEMURA, Takayuki MATSUZAKI, Yasuhiro MENJO, Shin MIYAMURA, Yohji SAKURAI, Akihito WATANABE, Yasuyo SAKATA, Takumi MASUMOTO, Kohei AKAZAWA, Haruhiko SUGINO, Naoki AMADA, Satoshi OHASHI, Tomoichi SHINOHARA, Hirofumi SASAKI, Chisako MORITA, Junko YAMASHITA, Satoko NAKAJIMA
  • Drug for preventing and/or treating polycystic kidney disease
    Patent number: 9669075
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: June 6, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • PHARMACEUTICAL PREPARATION COMPRISING BREXPIPRAZOLE AND SUBSTITUTED BETA-CYCLODEXTRIN
    Publication number: 20170151237
    Abstract: Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted ?-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted ?-cyclodextrin.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya HASEGAWA, Hidekazu TOYOBUKU
  • METHOD FOR MEASURING ANTI-WT1 ANTIBODY
    Publication number: 20170138958
    Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.
    Type: Application
    Filed: December 8, 2016
    Publication date: May 18, 2017
    Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruo SUGIYAMA, Yusuke OJI, Kiyonori KATSURAGI, Hideaki TANAKA, Shinji SOGO, Yoshihiro GOTO, Yasukazu OHMOTO, Husako IWATA
  • NOVEL LACTOBACILLUS PARACASEI STRAIN
    Publication number: 20170137902
    Abstract: A major object of the present invention is to provide an effective means for promoting polyamine synthesis in an organism (in particular, in humans). Lactobacillus paracasei having polyamine production promoting activity in an organism.
    Type: Application
    Filed: March 23, 2015
    Publication date: May 18, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi IKENAGA, Tsuneyuki NODA, Yoshito TAJIRI, Hiroki NOGUCHI, Atsushi UEDA, Noriyuki KOUDA
  • ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE
    Publication number: 20170136010
    Abstract: [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD
    Inventors: Haruka YOSHIDA, Toshiaki TANIGUCHI, Tadashi MUKAI